RARE:NGS-Ultragenyx Pharmaceutical Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 58.74

Change

+0.91 (+1.57)%

Market Cap

USD 3.30B

Volume

0.53M

Analyst Target

USD 85.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing RARE

GNOM Global X Genomics & Biote.. 4.73 % 0.00 %

+0.19 (+2.37%)

USD 0.08B
GNOG:LSE Global X Genomics & Biote.. 4.73 % 0.00 %

+0.14 (+2.37%)

USD 5.90M
GN0M:XETRA Global X Genomics & Biote.. 4.48 % 0.00 %

+0.16 (+2.37%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.48 % 0.00 %

+0.16 (+2.37%)

USD 6.07M
BBP Virtus LifeSci Biotech Pr.. 2.01 % 0.79 %

+0.30 (+2.37%)

USD 0.02B
WBIO:LSE WisdomTree BioRevolution .. 1.85 % 0.00 %

+29.20 (+2.37%)

USD 3.72M
WRNA:XETRA WisdomTree BioRevolution .. 1.75 % 0.00 %

+0.31 (+2.37%)

USD 2.77M
IS0R:XETRA iShares High Yield Corpor.. 0.32 % 0.00 %

+0.23 (+2.37%)

USD 2.71B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.05 (+2.37%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

+0.25 (+2.37%)

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.84% 73% C 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.84% 73% C 81% B-
Trailing 12 Months  
Capital Gain 55.89% 80% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.89% 80% B- 88% B+
Trailing 5 Years  
Capital Gain 33.20% 75% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.20% 75% C 64% D
Average Annual (5 Year Horizon)  
Capital Gain 10.68% 66% D+ 67% D+
Dividend Return 10.68% 66% D+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 73.47% 45% F 24% F
Risk Adjusted Return 14.53% 74% C 51% F
Market Capitalization 3.30B 95% A 88% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 11.87 12% 9%
Price / Cash Flow Ratio -10.89 83% 85%
Price/Free Cash Flow Ratio -6.46 83% 84%
Management Effectiveness  
Return on Equity -208.43% 23% 11%
Return on Invested Capital -180.72% 13% 5%
Return on Assets -23.42% 67% 22%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector